Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding (English)
Free access
- New search for: Yu, Zhe
- New search for: Gao, Ling
- New search for: Zang, Yinshan
- New search for: Cheng, Lu
- New search for: Gao, Wenjia
- New search for: Xu, Yan
In:
Immunity, Inflammation and Disease
;
12
, 2
;
2024
More details on this result
-
Title:Adalimumab exhibits superiority over etanercept in terms of a numerically higher response rate and equivalent adverse events: A real‐world finding
-
Contributors:Yu, Zhe (author) / Gao, Ling (author) / Zang, Yinshan (author) / Cheng, Lu (author) / Gao, Wenjia (author) / Xu, Yan (author)
-
Published in:
-
Issue:2
-
Publication date:2024-02-01
-
Size:11 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Keywords:
German copyright law applies. The work or content may be downloaded, consumed, stored or printed for your own use but it may not be distributed via the internet or passed on to external parties.